Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer

Clinical Cancer Research

Volumn 14, Issue 2, 2008, Pages 412-418

  Winter, Jordan M ^a   Ting, Angela H ^a   Vilardell, Felip ^a   Gallmeier, Eike ^a   Baylin, Steve B ^a   Hruban, Ralph H ^a   Kern, Scott E ^a   Iacobuzio Donahue, Christine A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; UVOMORULIN;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL MEMBRANE; CONTROLLED STUDY; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METHYLATION; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNET RING CARCINOMA; UNDIFFERENTIATED CARCINOMA;

BETA CATENIN; CADHERINS; CARCINOMA, SIGNET RING CELL; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PANCREATIC NEOPLASMS; PROMOTER REGIONS (GENETICS);

EID: 38949178861     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0487     Document Type: Article

References (42)

1. Embuscado EE, Laheru D, Ricci F, et al. Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther 2005;4:548-54.
2. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-3.
3. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000;60:2002-6.
4. Xin W, Yun KJ, Ricci F, et al. MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course. Clin Cancer Res 2004;10:8516-20.
5. Bortolasi L, Burgart LJ, Tsiotos GG, Luque-De Leon E, Sarr MG. Adenocarcinoma of the distal bile duct. A clinicopathologic outcome analysis after curative resection. Dig Surg 2000;17:36-41.
6. Rijken AM, Hu J, Perlman EJ, et al. Genomic alterations in distal bile duct carcinoma by comparative genomic hybridization and karyotype analysis. Genes Chromosomes Cancer 1999;26:185-91.
7. Zerbi A, Balzano G, Leone BE, Angeli E, Veronesi P, Di Carlo V. Clinical presentation, diagnosis and survival of resected distal bile duct cancer. Dig Surg 1998;15:410-6.
8. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: anovel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci US A1996;93:9821-6.
9. Graff JR, Herman JG, Lapidus RG, et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 1995;55:5195-9.
10. Caca K, Kolligs FT, Ji X, et al. β- and γ-catenin mutations, but not E-cadherin inactivation, underlie T-cell factor/lymphoid enhancer factor transcriptional deregulation in gastric and pancreatic cancer. Cell Growth Differ 1999;10:369-76.
11. Frixen UH, Behrens J, Sachs M, et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991;113:173-85.
12. Chen WH, Horoszewicz JS, Leong SS, et al. Human pancreatic adenocarcinoma: in vitro and in vivo morphology of a new tumor line established from ascites. In Vitro 1982;18:24-34.
13. Tan MH, Nowak NJ, Loor R, et al. Characterization of a new primary human pancreatic tumor line. Cancer Invest 1986;4:15-23.
14. Hruban RH, Klimstra DS, Pitman MB. Tumors of the pancreas. 4th ed. Washington (DC): Armed Forces Institute of Pathology; 2006.
15. Peters, K and Kloppel, G [Undifferentiated pancreatic carcinomas. Leap into chaos]. Pathologe 2005;26:18-21.
16. Paal E, Thompson LD, Frommelt RA, Przygodzki RM, Heffess CS. A clinicopathologic and immunohistochemical study of 35 anaplastic carcinomas of the pancreas with a review of the literature. Ann Diagn Pathol 2001;5:129-40.
17. Chen J, Baithun SI. Morphological study of 391 cases of exocrine pancreatic tumours with special reference to the classification of exocrine pancreatic carcinoma. J Pathol 1985;146:17-29.
18. Wilentz RE, Hruban RH. Pathology of cancer of the pancreas. Surg Oncol Clin N Am 1998;7:43-65.
19. Winter JM, Cameron JL, Campbell KC, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single institution experience. J Gastrointest Surg 2006;10:1199-211.
20. Ogutu EO. The pattern of pancreatic carcinoma at Kenyatta National Hospital. East Afr Med J 1989;66:105-8.
21. Tschang TP, Garza-Garza R, Kissane JM. Pleomorphic carcinoma of the pancreas: an analysis of 15 cases. Cancer 1977;39:2114-26.
22. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003;15:740-6.
23. Karayiannakis AJ, Syrigos KN, Chatzigianni E, et al. Aberrant E-cadherin expression associated with loss of differentiation and advanced stage in human pancreatic cancer. Anticancer Res1998;18:4177-80.
24. Pignatelli M, Ansari TW, Gunter P, et al. Loss of membranous E-cadherin expression in pancreatic cancer: correlation with lymph node metastasis, high grade, and advanced stage. J Pathol 1994;174:243-8.
25. Weinel RJ, Neumann K, Kisker O, Rosendahl A. Expression and potential role of E-cadherin in pancreatic carcinoma. Int J Pancreatol 1996;19:25-30.
26. Sedivy R, Peters K, Kloppel G. Osteopontin expression in ductal adenocarcinomas and undifferentiated carcinomas of the pancreas. Virchows Arch 2005;446:41-5.
27. Yonemasu H, Takashima M, Nishiyama KI, et al. Phenotypical characteristics of undifferentiated carcinoma of the pancreas: a comparison with pancreatic ductal adenocarcinoma and relevance of E-cadherin, a catenin and h catenin expression. Oncol Rep 2001;8:745-52.
28. Chan JK, Wong CS. Loss of E-cadherin is the fundamental defect in diffuse-type gastric carcinoma and infiltrating lobular carcinoma of the breast. Adv Anat Pathol 2001;8:165-72.
29. De Leeuw WJ, Berx G, Vos CB, et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol 1997;183:404-11.
30. Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med 1995;333:32-41.
31. Merino MJ, Livolsi VA. Signet ring carcinoma of the female breast: a clinicopathologic analysis of 24 cases. Cancer 1981;48:1830-7.
32. Muta H, Noguchi M, Kanai Y, Ochiai A, Nawata H, Hirohashi S. E-cadherin gene mutations in signet ring cell carcinoma of the stomach. Jpn J Cancer Res 1996;87:843-8.
33. Vos CB, Cleton-Jansen AM, Berx G, et al. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer 1997;76:1131-3.
34. Huntsman DG, Carneiro F, Lewis FR, et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl JMed 2001;344:1904-9.
35. Keller G, Vogelsang H, Becker I, et al. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol 1999;155:337-42.
36. Dimet S, Lazure T, Bedossa P. Signet-ring cell change in acute erosive gastropathy. Am J Surg Pathol 2004;28:1111-2.
37. Wang K, Weinrach D, Lal A, et al. Signet-ring cell change versus signet-ring cell carcinoma: a comparative analysis. Am J Surg Pathol 2003;27:1429-33.
38. Iacobuzio-Donahue CA, van der Heijden MS, Baumgartner MR, et al. Large-scale allelotype of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss. Cancer Res 2004;64:871-5.
39. Berx G, Becker KF, Hofler H, van Roy F. Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 1998;12:226-37.
40. Strathdee G. Epigenetic versus genetic alterations in the inactivation of E-cadherin. Semin Cancer Biol 2002;12:373-9.
41. Cano A, Perez-Moreno MA, Rodrigo I, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000;2:76-83.
42. Hruban RH, Wilentz RE, Kern SE. Genetic progression in the pancreatic ducts. Am J Pathol 2000;156:1821-5.